Post-coronavirus remote myocarditis: a case report and review of the literature
DOI:
https://doi.org/10.66636/gmj.v1.i2.a95Keywords:
COVID-19, SARS-CoV-2, Myocarditis, Cardiac MRI, Chest pain, Coronary angiography, Cardiovascular complications, Post-COVID syndrome, Remote myocarditis, Case reportAbstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19, which was declared a global public health emergency in March 2020. Beyond respiratory disease, SARS-CoV-2 has demonstrated harmful effects on the cardiovascular system, including myocardial injury and myocarditis. Prior coronavirus infections, including MERS-CoV, have been associated with myocarditis through direct cardiomyocyte invasion, systemic inflammation, and immune-mediated mechanisms.
Case presentation We present a 54-year-old woman with a family history of ischaemic heart disease who presented with chest pain and palpitations one year after COVID-19 infection. Echocardiography showed mild left ventricular dysfunction (ejection fraction 50%). Exercise stress testing revealed deep T-wave inversions in leads II, III, and V3–V6. Inflammatory markers were elevated (ESR 39 mm/h; CRP 24.6 mg/L). Coronary angiography demonstrated normal coronary arteries. Cardiac MRI fulfilled diagnostic criteria for remote myocarditis.
Conclusions This case illustrates that COVID-19-associated myocarditis can present remotely, mimicking angina with ischaemic ECG changes, and underscores the importance of a structured diagnostic pathway including cardiac MRI when coronary anatomy is normal. Clinicians should maintain a high index of suspicion for myocarditis in patients with post-COVID cardiac symptoms, even when the acute infection occurred months earlier.
Keywords chest pain; coronary artery disease; exercise stress test; cardiac MRI; myocarditis; COVID-19; case report
References
1. Ruiz Mercedes B, Serwat A, Karout L. New-onset
myocardial injury in pregnant patients with coronavirus
disease 2019: a case series of 15 patients. Am J
Obstet Gynecol. 2021;224(4):387.e1–9.
https://doi.org/10.1016/j.ajog.2020.10.028
2. Babapoor-Farrokhran S, Gill D, Amanullah A. Myocardial
injury and COVID-19: possible mechanisms. Life Sci.
2020;253:117723.
https://doi.org/10.1016/j.lfs.2020.117723
3. Tajbakhsh A, Gheibi Hayat SM, Inabadi M. COVID-19
and cardiac injury: clinical manifestations, biomarkers,
mechanisms, diagnosis, treatment, and follow up.
Expert Rev Anti Infect Ther. 2021;19(3):345–357.
https://doi.org/10.1080/14787210.2020.1822737
4. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular
considerations for patients, health care workers, and
health systems during the COVID-19 pandemic. J Am
Coll Cardiol. 2020;75(18):2352–2371.
https://doi.org/10.1016/j.jacc.2020.03.031
5. Alhogbani T. Acute myocarditis associated with novel
Middle East respiratory syndrome coronavirus. Ann
Saudi Med. 2016;36(1):78–80.
https://doi.org/10.5144/0256-4947.2016.78
6. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential
novel etiology of fulminant myocarditis. Herz.
2020;45(3):230–232. https://doi.org/10.1007/s00059-
020-04909-z
11. Guo T, Fan Y, Chen M, et al. Cardiovascular
implications of fatal outcomes of patients with
coronavirus disease 2019 (COVID-19). JAMA Cardiol.
2020;5(7):811–818.
https://doi.org/10.1001/jamacardio.2020.1017
12. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al.
Association between hospitalization for pneumonia and
subsequent risk of cardiovascular disease. JAMA.
2015;313(3):264–274.
https://doi.org/10.1001/jama.2014.18229
13. Chen T, Wu D, Chen H, et al. Clinical characteristics of
113 deceased patients with coronavirus disease 2019:
retrospective study. BMJ. 2020;368:m1091.
https://doi.org/10.1136/bmj.m1091
14. Huang C, Wang Y, Li X, et al. Clinical features of
patients infected with 2019 novel coronavirus in
Wuhan, China. Lancet. 2020;395(10223):497–506.
https://doi.org/10.1016/S0140-6736(20)30183-5
15. Zhou F, Yu T, Du R, et al. Clinical course and risk
factors for mortality of adult inpatients with COVID-19
in Wuhan, China: a retrospective cohort study. Lancet.
2020;395(10229):1054–1062.
https://doi.org/10.1016/S0140-6736(20)30566-3
16. Wang D, Hu B, Hu C, et al. Clinical characteristics of
138 hospitalized patients with 2019 novel coronavirus-
infected pneumonia in Wuhan, China. JAMA.
2020;323(11):1061–1069.
https://doi.org/10.1001/jama.2020.1585
17. Wu Z, McGoogan JM. Characteristics of and important
lessons from the coronavirus disease 2019 (COVID-19)
outbreak in China. JAMA. 2020;323(13):1239–1242.
https://doi.org/10.1001/jama.2020.2648
18. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical
predictors of mortality due to COVID-19 based on an
analysis of data of 150 patients from Wuhan, China.
Intensive Care Med. 2020;46(5):846–848.
https://doi.org/10.1007/s00134-020-05991-x
19. Long B, Brady WJ, Koyfman A, Gottlieb M.
Cardiovascular complications in COVID-19. Am J
Emerg Med. 2020;38(7):1504–1507.
https://doi.org/10.1016/j.ajem.2020.04.048
20. Ali M, Shiwani HA, Eroume-A Egom E. COVID-19 and
myocarditis: a review of literature. Egypt Heart J.
2022;74(1):23. https://doi.org/10.1186/s43044-022-
00260-2
7. Liu K, Fang YY, Deng Y, et al. Clinical characteristics of
novel coronavirus cases in tertiary hospitals in Hubei
Province. Chin Med J (Engl). 2020;133(9):1025–1031.
https://doi.org/10.1097/CM9.0000000000000744
8. Xu Z, Shi L, Wang Y, et al. Pathological findings of
COVID-19 associated with acute respiratory distress
syndrome. Lancet Respir Med. 2020;8(4):420–422.
https://doi.org/10.1016/S2213-2600(20)30076-X
9. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical
indexes from 2019-nCoV infected patients linked to
viral loads and lung injury. Sci China Life Sci.
2020;63(3):364–374. https://doi.org/10.1007/s11427-
020-1643-8
10. Shi S, Qin M, Shen B, et al. Association of cardiac
injury with mortality in hospitalized patients with
COVID-19 in Wuhan, China. JAMA Cardiol.
2020;5(7):802–810.
https://doi.org/10.1001/jamacardio.2020.0950
21. Siripanthong B, Nazarian S, Muser D, et al.
Recognizing COVID-19-related myocarditis: the
possible pathophysiology and proposed guideline for
diagnosis and management. Heart Rhythm.
2020;17(9):1463–1471.
https://doi.org/10.1016/j.hrthm.2020.05.001
22. Cooper LT Jr. Myocarditis. N Engl J Med.
2009;360(15):1526–1538.
https://doi.org/10.1056/NEJMra0800028
23. Baboonian C, Treasure T. Meta-analysis of the
association of enteroviruses with human heart disease.
Heart. 1997;78(6):539–543.
https://doi.org/10.1136/hrt.78.6.539
24. Caforio ALP, Calabrese F, Angelini A, et al. A
prospective study of biopsy-proven myocarditis:
prognostic relevance of clinical and aetiopathogenetic
features at diagnosis. Eur Heart J. 2007;28(11):1326–
1333. https://doi.org/10.1093/eurheartj/ehm076
25. Agrawal AS, Garron T, Tao X, et al. Generation of a
transgenic mouse model of Middle East respiratory
syndrome coronavirus infection and disease. J Virol.
gmj.ge | ISSN 3088-4322 | doi:10.66636/gmj.v1.i2.a95 | CC BY 4.0
Davarashvili I. GMJ (2026) 1(2):a95 Page 7 of 8
2015;89(7):3659–3670.
https://doi.org/10.1128/JVI.03427-14
26. Esfandiarei M, McManus BM. Molecular biology and
pathogenesis of viral myocarditis. Annu Rev Pathol.
2008;3:127–155.
https://doi.org/10.1146/annurev.pathmechdis.3.121806.
151534
27. Seko Y, Takahashi N, Yagita H, Okumura K, Yazaki Y.
Expression of cytokine mRNAs in murine hearts with
acute myocarditis caused by coxsackievirus B3. J
Pathol. 1997;183(1):105–108.
https://doi.org/10.1002/(SICI)1096-
9896(199709)183:1<105::AID-PATH1094>3.0.CO;2-B
28. Cihakova D, Sharma R, Fairweather D, Afanasyeva M,
Rose N. Animal models for autoimmune myocarditis
and autoimmune thyroiditis. Methods Mol Med.
2004;102:175–193. https://doi.org/10.1385/1-59259-
805-6:175
29. Zhang P, Cox CJ, Alvarez KM, Cunningham MW.
Cutting edge: cardiac myosin activates innate immune
responses through TLRs. J Immunol. 2009;183(1):27–
31. https://doi.org/10.4049/jimmunol.0800861
30. Blyszczuk P, Kania G, Dieterle T, et al. Myeloid
differentiation factor-88/interleukin-1 signaling controls
cardiac fibrosis and heart failure progression in
inflammatory dilated cardiomyopathy. Circ Res.
2009;105(9):912–920.
https://doi.org/10.1161/CIRCRESAHA.109.199802
31. Baldeviano GC, Barin JG, Talor MV, et al. Interleukin-
17A is dispensable for myocarditis but essential for the
progression to dilated cardiomyopathy. Circ Res.
2010;106(10):1646–1655.
https://doi.org/10.1161/CIRCRESAHA.109.213157
32. Oleszak F, Maryniak A, Botti E, et al. Myocarditis
associated with COVID-19. Am J Med Case Rep.
2020;8(12):498–502. https://doi.org/10.12691/ajmcr-8-
12-19
33. Fox SE, Falgout L, Vander Heide RS. COVID-19
myocarditis: quantitative analysis of the inflammatory
infiltrate and a proposed mechanism. Cardiovasc
Pathol. 2021;54:107361.
https://doi.org/10.1016/j.carpath.2021.107361
34. Lee DW, Gardner R, Porter DL, et al. Current concepts
in the diagnosis and management of cytokine release
syndrome. Blood. 2014;124(2):188–195.
https://doi.org/10.1182/blood-2014-05-552729
35. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M.
The cytokine storm in COVID-19: an overview of the
involvement of the chemokine/chemokine-receptor
system. Cytokine Growth Factor Rev. 2020;53:25–32.
https://doi.org/10.1016/j.cytogfr.2020.05.003
36. Kawakami R, Sakamoto A, Kawai K, et al. Pathological
evidence for SARS-CoV-2 as a cause of myocarditis:
JACC review topic of the week. J Am Coll Cardiol.
2021;77(3):314–325.
https://doi.org/10.1016/j.jacc.2020.11.031
37. Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent
randomized trials of antithrombotic therapy for patients
with COVID-19: JACC state-of-the-art review. J Am
Coll Cardiol. 2021;77(15):1903–1921.
https://doi.org/10.1016/j.jacc.2021.02.035
38. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19
and the cardiovascular system: implications for risk
assessment, diagnosis, and treatment options.
Cardiovasc Res. 2020;116(10):1666–1687.
https://doi.org/10.1093/cvr/cvaa106
39. Guo T, Fan Y, Chen M, et al. Cardiovascular
implications of fatal outcomes of patients with
coronavirus disease 2019 (COVID-19). JAMA Cardiol.
2020;5(7):811–818.
https://doi.org/10.1001/jamacardio.2020.1017
40. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of
cardiovascular magnetic resonance imaging in patients
recently recovered from coronavirus disease 2019
(COVID-19). JAMA Cardiol. 2020;5(11):1265–1273.
https://doi.org/10.1001/jamacardio.2020.3557
41. Shi S, Qin M, Shen B, et al. Association of cardiac
injury with mortality in hospitalized patients with
COVID-19 in Wuhan, China. JAMA Cardiol.
2020;5(7):802–810.
https://doi.org/10.1001/jamacardio.2020.0950
42. Laganà N, Cei M, Evangelista I, et al. Suspected
myocarditis in patients with COVID-19: a multicenter
case series. Medicine. 2021;100(8):e24552.
https://doi.org/10.1097/MD.0000000000024552
43. Omidi F, Hajikhani B, Kazemi SN, et al. COVID-19 and
cardiomyopathy: a systematic review. Front Cardiovasc
Med. 2021;8:695206.
https://doi.org/10.3389/fcvm.2021.695206
44. Pan D, Sze S, Minhas JS, et al. The impact of ethnicity
on clinical outcomes in COVID-19: a systematic review.
EClinicalMedicine. 2020;23:100404.
https://doi.org/10.1016/j.eclinm.2020.100404
45. Myers VD, Gerhard GS, McNamara DM, et al.
Association of variants in BAG3 with cardiomyopathy
outcomes in African American individuals. JAMA
Cardiol. 2018;3(10):929–938.
https://doi.org/10.1001/jamacardio.2018.2541
46. Leigh JA, Alvarez M, Rodriguez CJ. Ethnic minorities
and coronary heart disease: an update and future
directions. Curr Atheroscler Rep. 2016;18(2):9.
https://doi.org/10.1007/s11883-016-0559-4
47. Abuelgasim E, Saw LJ, Shirke M, Zeinah M, Harky A.
COVID-19: unique public health issues facing Black,
Asian and minority ethnic communities. Curr Probl
Cardiol. 2020;45(8):100621.
https://doi.org/10.1016/j.cpcardiol.2020.100621
48. Vinciguerra M, Greco E. SARS-CoV-2 and black
population: ACE2 as shield or blade? Infect Genet
Evol. 2020;84:104361.
https://doi.org/10.1016/j.meegid.2020.104361
49. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and
disqualification recommendations for competitive
athletes with cardiovascular abnormalities: task force 3.
Circulation. 2015;132(22):e273–e280.
https://doi.org/10.1161/CIR.0000000000000239
50. Daniels CJ, Rajpal S, Greenshields JT, et al.
Prevalence of clinical and subclinical myocarditis in
competitive athletes with recent SARS-CoV-2 infection.
JAMA Cardiol. 2021;6(9):1078–1087.
https://doi.org/10.1001/jamacardio.2021.2065
51. Rajpal S, Tong MS, Borchers J, et al. Cardiovascular
magnetic resonance findings in competitive athletes
recovering from COVID-19 infection. JAMA Cardiol.
2021;6(1):116–118.
https://doi.org/10.1001/jamacardio.2020.4916
52. Al-Akchar M, Kiel J. Acute myocarditis. In: StatPearls.
Treasure Island (FL): StatPearls Publishing; 2023.
53. Marcinkiewicz K, Petryka-Mazurkiewicz J, Nowicki M, et
al. Acute heart failure in the course of fulminant
myocarditis requiring mechanical circulatory support in
a healthy young patient after COVID-19. Kardiol Pol.
gmj.ge | ISSN 3088-4322 | doi:10.66636/gmj.v1.i2.a95 | CC BY 4.0
Davarashvili I. GMJ (2026) 1(2):a95 Page 8 of 8
2021;79(5):583–584.
https://doi.org/10.33963/KP.15929
54. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac
involvement in a patient with coronavirus disease 2019
(COVID-19). JAMA Cardiol. 2020;5(7):819–824.
https://doi.org/10.1001/jamacardio.2020.1096
55. Kim IC, Kim JY, Kim HA, Han S. COVID-19-related
myocarditis in a 21-year-old female patient. Eur Heart
J. 2020;41(19):1859.
https://doi.org/10.1093/eurheartj/ehaa288
56. Ho JS, Sia CH, Chan MY, Lin W, Wong RC.
Coronavirus-induced myocarditis: a meta-summary of
cases. Heart Lung. 2020;49(6):681–685.
https://doi.org/10.1016/j.hrtlng.2020.08.013
57. Das BB. SARS-CoV-2 myocarditis in a high school
athlete after COVID-19 and its implications for
clearance for sports. Children. 2021;8(6):427.
https://doi.org/10.3390/children8060427
58. Fried JA, Ramasubbu K, Bhatt R, et al. The variety of
cardiovascular presentations of COVID-19. Circulation.
2020;141(23):1930–1936.
https://doi.org/10.1161/CIRCULATIONAHA.120.04716
4
59. Okor I, Sleem A, Zhang A, Kadakia R, Bob-Manuel T,
Krim SR. Suspected COVID-19-induced
myopericarditis. Ochsner J. 2021;21(2):181–186.
https://doi.org/10.31486/toj.20.0091
60. Gaine S, Devitt P, Coughlan JJ, Pearson I. COVID-19-
associated myocarditis presenting as new-onset heart
failure and atrial fibrillation. BMJ Case Rep.
2021;14(7):e244027. https://doi.org/10.1136/bcr-2021-
244027
parvovirus B19 presence. Eur J Heart Fail.
2018;20(3):609.
69. Abdelnabi M, Eshak N, Saleh Y, Almaghraby A.
Coronavirus disease 2019 myocarditis: insights into
pathophysiology and management. Eur Cardiol Rev.
2020;15:e63. https://doi.org/10.15420/ecr.2020.31
70. Sawalha K, Abozenah M, Kadado AJ, et al. Systematic
review of COVID-19 related myocarditis: insights on
management and outcome. Cardiovasc Revasc Med.
2021;23:107–113.
https://doi.org/10.1016/j.carrev.2020.08.028
71. Chen HS, Wang W, Wu SN, Liu JP. Corticosteroids for
viral myocarditis. Cochrane Database Syst Rev. 2013;
(10):CD004471.
https://doi.org/10.1002/14651858.CD004471.pub3
72. Tschöpe C, Cooper LT, Torre-Amione G, van Linthout
S. Management of myocarditis-related cardiomyopathy
in adults. Circ Res. 2019;124(11):1568–1583.
https://doi.org/10.1161/CIRCRESAHA.118.313578
73. Welt FGP, Shah PB, Aronow HD, et al. Catheterization
laboratory considerations during the coronavirus
(COVID-19) pandemic. J Am Coll Cardiol.
2020;75(18):2372–2375.
https://doi.org/10.1016/j.jacc.2020.03.021
74. Zhao H, Zhu Q, Zhang C, et al. Tocilizumab combined
with favipiravir in the treatment of COVID-19: a
multicenter trial in a small sample size. Biomed
Pharmacother. 2021;133:1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ilia Davarashvili
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is published open access under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence.
You are free to: share and adapt the work for any purpose, even commercially.
Conditions: provide appropriate credit to the authors and the Georgian Medical Journal (GMJ), link to the licence, and indicate if changes were made. Do not apply legal terms or technological measures that legally restrict others from doing anything the licence permits.
Licence: creativecommons.org/licenses/by/4.0 · Legal code: creativecommons.org/licenses/by/4.0/legalcode
Third-party material. Images or other content credited to a third party are not covered by CC BY 4.0; permission must be obtained from the rights holder for reuse beyond statutory exceptions.
Authors' rights. Authors retain copyright. First publication rights are granted to GMJ.
Data and code. Where provided, datasets or code may carry their own licences; please follow the licence stated in the article or repository record.
Listen on Spotify
Apple Podcasts
YouTube
Amazon Music
Castbox
Pocket Casts
LinkedIn
Facebook
X
Instagram
Substack
Bluesky
ResearchGate
